U.S. Markets closed

Shire plc (SHP.L)


LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
4,651.50-86.50 (-1.83%)
At close: 5:04PM BST
People also watch
SN.LWPP.LAZN.LSMIN.LSDR.L

Shire plc

5 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
353 1 429 7700
http://www.shire.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees23,906

Key Executives

NameTitlePayExercisedAge
Dr. Flemming Ornskov M.D., MBA, MPHChief Exec. Officer, Managing Director and Exec. Director5.43MN/A59
Mr. Jeffrey PoultonChief Financial Officer and Exec. Director1.62MN/A49
Mr. Matthew Walker BSCHEHead of Technical OperationsN/AN/A53
Mr. William Richard MordanGen. Counsel and Corp. Sec.N/AN/A47
Mrs. Jessica MannSr. VP of Global Corp. CommunicationsN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Shire plc, a biotechnology company, focused on serving people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Its marketed products include ADVATE and ADYNOVATE/ADYNOVI for hemophilia A; RIXUBIS to treat hemophilia B; VONVENDI for the treatment of von willebrand Disease; FEIBA to treat hemophilia A and B patients with inhibitors; CINRYZE and FIRAZYR for hereditary angioedema; ELAPRASE to treat hunter syndrome; REPLAGAL for Fabry disease; and VPRIV to treat type 1 Gaucher disease. The company marketed products also comprise of VYVANSE/VENVANSE/ELVANSE/TYVENSE/VUXEN/ADUVANZ for the treatment of attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder; ADDERALL XR to treat ADHD; GAMMAGARD LIQUID/KIOVIG, GAMMAGARD S/D, HYQVIA, and CUVITRU for the treatment of primary immunodeficiency; and FLEXBUMIN to treat hypovolemia and hypoalbuminemia. In addition, its marketed products consists of LIALDA/MEZAVANT for ulcerative colitis; GATTEX/REVESTIVE to treat short bowel syndrome; NATPARA for the control of hypocalcemia in patients with hypoparathyroidism; ONCASPAR to treat acute lymphoblastic leukemia; ONYVIDE for metastatic adenocarcinoma of the pancreas; and XIIDRA to treat dry eye disease. The company markets its products through wholesalers, distribution centers, and pharmacies. It has collaborative and other licensing arrangements with Pfizer Inc.; Precision BioSciences; Symphogen; Merrimack Pharmaceuticals, Inc.; Coherus Biosciences, Inc.; Momenta Pharmaceuticals, Inc.; and SFJ Pharmaceuticals Group. Shire plc was founded in 1986 and is based in Dublin, Ireland.

Corporate Governance

Shire plc’s ISS Governance QualityScore as of May 1, 2017 is 6. The pillar scores are Audit: 10; Board: 1; Shareholder Rights: 1; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.